MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor
Our findings suggest that the combination of MEKis and PDGFR and/or RAF dimer inhibitors can overcome MEKi resistance and may serve as a novel targeted therapeutic strategy for patients with NF1-deficient MPNST, which in turn could impact future clinical investigations for this patient population.
Authors
- Amish J. Patel (ORCID: https://orcid.org/0000-0002-4214-2619)
- Miguel A. Miranda-Román (ORCID: https://orcid.org/0000-0003-4914-848X)
- Makhzuna N. Khudoynazarova
- Ping Chi
- Cindy J. Lee (ORCID: https://orcid.org/0000-0002-2613-4387)
- Sarah Warda (ORCID: https://orcid.org/0000-0001-8067-8804)
- Mohini R. Pachai (ORCID: https://orcid.org/0000-0003-1143-0607)
- Juan Yan (ORCID: https://orcid.org/0000-0001-7130-945X)
- Eve Fishinevich (ORCID: https://orcid.org/0000-0002-1808-9213)
- Yu Chen (ORCID: https://orcid.org/0000-0002-0171-3884)
- Leili Ran
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1750
- Citations
- 6
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 2.21
Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Deciphera Pharmaceuticals
- Cycle for Survival
- National Institutes of Health
- National Cancer Institute